[{"address1": "171 Oyster Point Boulevard", "address2": "Suite 400", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 489 9000", "website": "https://www.surrozen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-\u00df, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 40, "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig C. Parker M.B.A.", "age": 63, "title": "CEO, President & Director", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 892375, "exercisedValue": 0, "unexercisedValue": 165332}, {"maxAge": 1, "name": "Mr. Charles  Williams", "age": 45, "title": "COO & Corporate Secretary", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 647639, "exercisedValue": 0, "unexercisedValue": 48919}, {"maxAge": 1, "name": "Dr. Li  Yang Ph.D.", "age": 56, "title": "Executive Vice President of Research", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 579850, "exercisedValue": 0, "unexercisedValue": 35138}, {"maxAge": 1, "name": "Dr. K. Christopher  Garcia Ph.D.", "title": "Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Roeland  Nusse Ph.D.", "age": 75, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1950, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Calvin  Kuo M.D., Ph.D.", "title": "Co-Founder & Member of Scientific Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Maleki", "age": 36, "title": "CFO & Principal Financial & Accounting Officer", "yearBorn": 1989, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel L. Chao M.D., Ph.D.", "title": "VP and Head of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Esther  Jhun", "title": "Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 20.0, "open": 20.51, "dayLow": 20.0, "dayHigh": 21.4, "regularMarketPreviousClose": 20.0, "regularMarketOpen": 20.51, "regularMarketDayLow": 20.0, "regularMarketDayHigh": 21.4, "payoutRatio": 0.0, "beta": 0.579, "forwardPE": -4.1753654, "volume": 45006, "regularMarketVolume": 45006, "averageVolume": 90643, "averageVolume10days": 85660, "averageDailyVolume10Day": 85660, "bid": 19.58, "ask": 20.4, "bidSize": 1, "askSize": 1, "marketCap": 171428416, "fiftyTwoWeekLow": 5.9, "fiftyTwoWeekHigh": 24.94, "allTimeHigh": 210.0, "allTimeLow": 4.5, "priceToSalesTrailing12Months": 47.566154, "fiftyDayAverage": 18.19914, "twoHundredDayAverage": 12.392805, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 97175424, "profitMargins": 0.0, "floatShares": 3487883, "sharesOutstanding": 8571421, "sharesShort": 200478, "sharesShortPriorMonth": 149882, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.0234, "heldPercentInsiders": 0.04143, "heldPercentInstitutions": 0.84507006, "shortRatio": 1.8, "shortPercentOfFloat": 0.026400002, "impliedSharesOutstanding": 8571421, "bookValue": -2.744, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -86906000, "trailingEps": -17.59, "forwardEps": -4.79, "lastSplitFactor": "1:15", "lastSplitDate": 1702512000, "enterpriseToRevenue": 26.963, "enterpriseToEbitda": -2.61, "52WeekChange": 0.5661707, "SandP52WeekChange": 0.14725316, "quoteType": "EQUITY", "currentPrice": 20.0, "targetHighPrice": 42.0, "targetLowPrice": 32.0, "targetMeanPrice": 36.66667, "targetMedianPrice": 36.0, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 81335000, "totalCashPerShare": 9.489, "ebitda": -37231000, "totalDebt": 7082000, "quickRatio": 12.853, "currentRatio": 13.153, "totalRevenue": 3604000, "revenuePerShare": 0.599, "returnOnAssets": -0.3348, "grossProfits": -22120000, "freeCashflow": -8879125, "operatingCashflow": -20951000, "revenueGrowth": -0.902, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -11.07325, "financialCurrency": "USD", "symbol": "SRZN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Surrozen, Inc.", "longName": "Surrozen, Inc.", "fiftyDayAverageChange": 1.8008595, "fiftyDayAverageChangePercent": 0.098952994, "twoHundredDayAverageChange": 7.607195, "twoHundredDayAverageChangePercent": 0.6138396, "priceToBook": -7.28863, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-08-12", "prevName": "Consonance-HFW Acquisition Corp.", "nameChangeDate": "2026-01-16", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1768597804, "regularMarketTime": 1768597201, "exchange": "NCM", "messageBoardId": "finmb_401948183", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1610375400000, "postMarketChangePercent": 0.0, "postMarketPrice": 20.0, "postMarketChange": 0.0, "regularMarketChange": 0.0, "regularMarketDayRange": "20.0 - 21.4", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 90643, "fiftyTwoWeekLowChange": 14.1, "fiftyTwoWeekLowChangePercent": 2.3898306, "fiftyTwoWeekRange": "5.9 - 24.94", "fiftyTwoWeekHighChange": -4.9400005, "fiftyTwoWeekHighChangePercent": -0.1980754, "fiftyTwoWeekChangePercent": 56.61707, "earningsTimestampStart": 1746821116, "earningsTimestampEnd": 1746821116, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -17.59, "epsForward": -4.79, "regularMarketChangePercent": 0.0, "regularMarketPrice": 20.0, "displayName": "Surrozen", "trailingPegRatio": null, "__fetch_time": "2026-01-17"}]